Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1987-9-30
|
pubmed:abstractText |
Rejection episodes in 259 heart allograft recipients and 29 heart-lung transplant patients at Stanford University were examined from the viewpoint of endomyocardial biopsy. The patients were divided into the following six groups by immunosuppressive regimen: Group 1 (100 patients) was treated with conventional immunosuppression. Group 2 (26 patients) was treated with cyclosporine in combination with low-dose corticosteroids and an initial 3- to 4-day course of rabbit antithymocyte globulin. Group 3 (76 patients) was treated with cyclosporine and low-dose corticosteroids. Group 4 (34 patients) was treated with low-dose cyclosporine, azathioprine, and low-dose corticosteroids. Group 5 (23 patients) was treated with low-dose cyclosporine and azathioprine, but initially without low-dose corticosteroids. Group 6 was composed of 29 heart-lung transplant recipients. Groups 1, 2, and 6 had significantly less rejection episodes than group 3, and groups 4 and 5 had more rejection episodes than group 3. In patients with a diagnosis of mild acute rejection on cyclosporine, a repeat biopsy shows progression to a moderate acute rejection in 21% to 43% of cases, emphasizing the importance of this diagnosis even in cyclosporine-treated patients. The characteristics of acute heart allograft rejection as assessed by endomyocardial biopsy are important to recognize. In part as a result of the data presented here, further modifications in the immunosuppressive regimen of the Stanford heart and heart-lung transplant recipients are being undertaken.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0887-2570
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-85
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3305819-Adolescent,
pubmed-meshheading:3305819-Adult,
pubmed-meshheading:3305819-Azathioprine,
pubmed-meshheading:3305819-Biopsy,
pubmed-meshheading:3305819-Child,
pubmed-meshheading:3305819-Child, Preschool,
pubmed-meshheading:3305819-Cyclosporins,
pubmed-meshheading:3305819-Drug Administration Schedule,
pubmed-meshheading:3305819-Endocardium,
pubmed-meshheading:3305819-Graft Rejection,
pubmed-meshheading:3305819-Heart,
pubmed-meshheading:3305819-Heart Transplantation,
pubmed-meshheading:3305819-Humans,
pubmed-meshheading:3305819-Immunosuppressive Agents,
pubmed-meshheading:3305819-Lung,
pubmed-meshheading:3305819-Lung Transplantation,
pubmed-meshheading:3305819-Middle Aged,
pubmed-meshheading:3305819-Myocardium,
pubmed-meshheading:3305819-Prednisone
|
pubmed:articleTitle |
Heart allograft rejection under varying immunosuppressive protocols as evaluated by endomyocardial biopsy.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|